Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DNA

DNA - Ginkgo Bioworks Holdings, Inc. Stock Price, Fair Value and News

$9.43-0.28 (-2.88%)
Market Closed

34/100

DNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

34/100

DNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.69

Target 3M

$9.67

Target 6M

$9.33

DNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DNA Price Action

Last 7 days

-3.6%

Last 30 days

15.4%

Last 90 days

-21.5%

Trailing 12 Months

-23.2%

DNA RSI Chart

DNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DNA Valuation

Market Cap

536.0M

Price/Earnings (Trailing)

-1.58

Price/Sales (Trailing)

2.97

EV/EBITDA

-1.69

Price/Free Cashflow

-2.86

DNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.69

Target 3M

$9.67

Target 6M

$9.33

DNA Fundamentals

DNA Revenue

Revenue (TTM)

180.6M

Rev. Growth (Yr)

-56.39%

Rev. Growth (Qtr)

-21.71%

DNA Earnings

Earnings (TTM)

-339.5M

Earnings Growth (Yr)

-43.18%

Earnings Growth (Qtr)

-33.92%

DNA Profitability

EBT Margin

-188.29%

Return on Equity

-60.66%

Return on Assets

-28.55%

Free Cashflow Yield

-34.92%

DNA Investor Care

Shares Dilution (1Y)

8.80%

Diluted EPS (TTM)

-6.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025237.4M230.8M180.6M0
2024208.7M184.3M218.0M227.0M
2023390.0M326.0M315.0M251.5M
2022438.1M539.1M527.9M477.7M
2021136.0M195.2M254.5M313.8M
20200065.4M76.7M
201900054.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Ginkgo Bioworks Holdings, Inc.

DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEginkgobioworks.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1292

Ginkgo Bioworks Holdings, Inc. Frequently Asked Questions

DNA is the stock ticker symbol of Ginkgo Bioworks Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ginkgo Bioworks Holdings, Inc. is 535.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DNA's fair value in chart for subscribers.

The fair value guage provides a quick view whether DNA is over valued or under valued. Whether Ginkgo Bioworks Holdings, Inc. is cheap or expensive depends on the assumptions which impact Ginkgo Bioworks Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNA.

As of Wed Jan 28 2026, DNA's PE ratio (Price to Earnings) is -1.58 and Price to Sales (PS) ratio is 2.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNA PE ratio will change depending on the future growth rate expectations of investors.